

[Fig. 1]



linear-linear
Plasma 305LO15 conc.(μg/mL)
3000.0
2500.0
2000.0
1500.0
1000.0
500.0
0.0
0
50
100
150
200
Time(Day)
Male
Female

1a



linear-linear
Plasma 305LO15 conc.(μg/mL)
2000
1800
1600
1400
1200
1000
800
600
400
200
0
0
50
100
150
200
Time(Day)
Male
Female

1b


[Fig. 2]


linear-linear
Plasma 305LO15 conc.(μg/mL)
3500
3000
2500
2000
1500
1000
500
0
0
50
100
150
200
Time(Day)
Male
Female


[Fig. 3a]


Plasma concentration of free-antigen (μg/mL)
120
100
80
60
40
20
0
0
10
20
30
40
50
60
70
80
90
100
Plasma 305LO15 conc.(μg/mL)
0.8 mg/kg IV
4 mg/kg IV
20 mg/kg IV
4 mg/kg SC


[Fig. 3b]


Absorbance
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0 50 100 150 200 250 300 350 400 450 500
Plasma 305LO15 conc.(μg/mL)
0.8 mg/kg IV
4 mg/kg IV
20 mg/kg IV
4 mg/kg SC


[Fig. 4a]


Part1, SAD
Plasma 305LO15 conc.(μg/mL)
100
10
1
0.1
0
50
100
150
200
Time(Day)
75 mg/head, IV
150 mg/head, IV
170 mg/head, SC


[Fig. 4b]


Part2, MAD
Plasma 305LO15 conc.(μg/mL)
1000
100
10
1
0
50
100
150
200
Time(Day)
170 mg/head, SC, QW


[Fig. 4c]


Part3, MAD
Plasma 305LO15 conc.(μg/mL)
1000
100
10
1
0.1
0
50
100
150
200
Time(Day)
170 mg/head, SC, QW
340 mg/head, SC, Q2W
600 mg/head, SC, Q4W


[Fig. 5]


pH7.4
Free Ag, Ab
Ag+Ab
2Ag+Ab
AU
min
pH6.0
Free Ag, Ab
AU
min
ECZ/hC5
ECZ/hC5/305LO15 1250
ECZ/hC5/305LO15 250
ECZ/hC5/305LO15 125
ECZ/hC5/305LO15 25


[Fig. 6]


75mg IV
95% Prediction Interval
Median of Prediction
C5 Inh Concentration (µg/mL)
50
40
30
20
10
0
0
20
40
60
Time (days)
11001
11004
11005


[Fig. 7]


125mg IV
95% Prediction Interval
Median of Prediction
C5 Inh Concentration (µg/mL)
80
70
60
50
40
30
20
10
0
0
10
20
30
40
50
Time (days)
11007
11008
11009


[Fig. 8]


100mg SC
95% Prediction Interval
Median of Prediction
C5 Inh Concentration (µg/mL)
0
10
20
30
40
0
10
20
30
40
50
Time (days)
11011
11013
11014

[Fig. 9]


PD Threshold
Ex vivo Dose Response Curve
Complete complement inhibition
Liposome Lysis (% of Baseline)
0
20
40
60
80
100
0
20
40
60
80
100
305LO15 concentration (µg/mL)

[Fig. 10a]



[Fig. 10b]

